A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimens of Tideglusib vs Placebo in Mild-to-Moderate AD Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimens of Tideglusib vs Placebo in Mild-to-Moderate AD Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2013

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ARGO
  • Most Recent Events

    • 17 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 11 Oct 2012 Results have been reported in a Noscira media release.
    • 11 Oct 2012 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has not been met according to a Noscira media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top